Trial Profile
A dose proportionality study of icotinib in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 05 Nov 2010 New trial record.